donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PKI PerkinElmer
150.740
-5.560-3.56%
Post Mkt Price
150.74000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/07/03(Q1)2022/04/03(FY)2022/01/02(Q4)2022/01/02
Total revenue
0.09% 1.23B -3.69% 1.26B 33.95% 5.07B 0.72% 1.36B
Operating revenue
0.09% 1.23B -3.69% 1.26B 33.95% 5.07B 0.72% 1.36B
Cost of revenue
3.71% 563.41M 11.04% 580.21M 32.46% 2.22B 16.62% 615.2M
Gross profit
-2.78% 666.16M -13.49% 679.23M 35.14% 2.85B -9.42% 749.12M
Operating expense
16.03% 403.38M 31.89% 411M 33.76% 1.5B 36.17% 435.57M
Selling and administrative expenses
17.11% 330.03M 33.01% 334.39M 33.73% 1.23B 35.05% 355.25M
Research and development costs
11.44% 73.35M 27.22% 76.61M 33.88% 274.97M 41.35% 80.32M
Operating profit
-22.15% 262.79M -43.35% 268.23M 36.71% 1.35B -38.18% 313.56M
Net non-operating interest income expense
-60.94% -26.37M -102.65% -27.79M -105.1% -99.89M -122.31% -26.8M
Non-operating interest income
107.63% 762K 44.77% 595K 121.88% 2.24M 164.08% 919K
Non-operating interest expense
61.96% 27.13M 100.96% 28.39M 105.44% 102.13M 123.48% 27.72M
Other net income (expense)
-344.39% -11.95M -210.44% -22.84M 198.21% 30.96M 213.06% 24.92M
Gain on sale of security
-66.29% 2.91M -162.83% -12.13M -- 10.99M -- 2.42M
Special income (charges)
-135.59% -11.93M -140.89% -13.38M -105.07% -16.43M -211.5% -3.41M
-Less:Restructuring and merger&acquisition
135.59% 11.93M 140.89% 13.38M 105.07% 16.43M 211.5% 3.41M
Other non- operating income (expenses)
-322.14% -2.93M -61.46% 2.67M 254.84% 36.41M 203.23% 25.92M
Income before tax
-31.16% 224.47M -54.71% 217.6M 41.21% 1.28B -34.12% 311.68M
Income tax
-43.54% 45.22M -59.86% 40.6M 88.82% 336.6M 42.99% 132.49M
Net income
-27.13% 179.21M -53.35% 176.96M 29.57% 943.16M -52.89% 179.18M
Net income continuous Operations
-27.12% 179.25M -53.34% 177M 29.55% 943.28M -52.9% 179.19M
Net income discontinuous operations
-5.26% -40K -7.89% -41K 40.28% -126K 95.89% -3K
Minority interest income
Net income attributable to the parent company
-27.13% 179.21M -53.35% 176.96M 29.57% 943.16M -52.89% 179.18M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-27.13% 179.21M -53.35% 176.96M 29.57% 943.16M -52.89% 179.18M
Basic earnings per share
-35.45% 1.42 -58.7% 1.4 24.35% 8.12 -58.2% 1.4198
Diluted earnings per share
-35.16% 1.42 -58.46% 1.4 24.5% 8.08 -58.28% 1.41
Dividend per share
0% 0.07 0% 0.07 0% 0.28 0% 0.07
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
CEO: Singh Ph.D., Prahlad R.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...